Literature DB >> 16716812

Pleural fibrosis.

Michael A Jantz1, Veena B Antony.   

Abstract

Pleural fibrosis can result from a variety of inflammatory processes. The response of the pleural mesothelial cell to injury and the ability to maintain its integrity are crucial in determining whether normal healing or pleural fibrosis occurs. The pleural mesothelial cell, various cytokines, and disordered fibrin turnover are involved in the pathogenesis of pleural fibrosis. The roles of these mediators in producing pleural fibrosis are examined. This article reviews the most common clinical conditions associated with the development of pleural fibrosis. Fibrothorax and trapped lung are two unique and uncommon consequences of pleural fibrosis. The management of pleural fibrosis, including fibrothorax and trapped lung, is discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16716812     DOI: 10.1016/j.ccm.2005.12.003

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  24 in total

1.  Plasminogen activator inhibitor-1 deficiency augments visceral mesothelial organization, intrapleural coagulation, and lung restriction in mice with carbon black/bleomycin-induced pleural injury.

Authors:  Torry A Tucker; Ann Jeffers; Alexia Alvarez; Shuzi Owens; Kathleen Koenig; Brandon Quaid; Andrey A Komissarov; Galina Florova; Hema Kothari; Usha Pendurthi; L Vijaya Mohan Rao; Steven Idell
Journal:  Am J Respir Cell Mol Biol       Date:  2014-02       Impact factor: 6.914

Review 2.  Intrapleural tissue plasminogen activator and deoxyribonuclease therapy for pleural infection.

Authors:  Francesco Piccolo; Natalia Popowicz; Donny Wong; Yun Chor Gary Lee
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

3.  Pleural effects of indium phosphide in B6C3F1 mice: nonfibrous particulate induced pleural fibrosis.

Authors:  Patrick J Kirby; Cassandra J Shines; Genie J Taylor; Ronald W Bousquet; Herman C Price; Jeffrey I Everitt; Daniel L Morgan
Journal:  Exp Lung Res       Date:  2009-12       Impact factor: 2.459

4.  Hemothorax: A Review of the Literature.

Authors:  Jacob Zeiler; Steven Idell; Scott Norwood; Alan Cook
Journal:  Clin Pulm Med       Date:  2020-01-10

5.  Syndrome of pleural and retrosternal "bridging" fibrosis and retroperitoneal fibrosis in patients with asbestos exposure.

Authors:  Vincent Cottin; Pierre-Yves Brillet; François Combarnous; Florence Duperron; Hilario Nunes; Jean-François Cordier
Journal:  BMJ Case Rep       Date:  2009-02-02

Review 6.  Inflammation-associated remodelling and fibrosis in the lung - a process and an end point.

Authors:  William A H Wallace; Paul M Fitch; A John Simpson; Sarah E M Howie
Journal:  Int J Exp Pathol       Date:  2007-04       Impact factor: 1.925

7.  Mesomesenchymal transition of pleural mesothelial cells is PI3K and NF-κB dependent.

Authors:  Shuzi Owens; Ann Jeffers; Jake Boren; Yoshikazu Tsukasaki; Kathleen Koenig; Mitsuo Ikebe; Steven Idell; Torry A Tucker
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-04-17       Impact factor: 5.464

Review 8.  Pleural mesothelial cells in pleural and lung diseases.

Authors:  Hitesh Batra; Veena B Antony
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

9.  Inhibition of Glycogen Synthase Kinase 3β Blocks Mesomesenchymal Transition and Attenuates Streptococcus pneumonia-Mediated Pleural Injury in Mice.

Authors:  Jake Boren; Grant Shryock; Alexis Fergis; Ann Jeffers; Shuzi Owens; Wenyi Qin; Kathleen B Koenig; Yoshikazu Tsukasaki; Satoshi Komatsu; Mitsuo Ikebe; Steven Idell; Torry A Tucker
Journal:  Am J Pathol       Date:  2017-11       Impact factor: 4.307

10.  Endothelial Cell Protein C Receptor Deficiency Attenuates Streptococcus pneumoniae-induced Pleural Fibrosis.

Authors:  Shiva Keshava; Jhansi Magisetty; Torry A Tucker; Weshely Kujur; Sachin Mulik; Charles T Esmon; Steven Idell; L Vijaya Mohan Rao; Usha R Pendurthi
Journal:  Am J Respir Cell Mol Biol       Date:  2021-04       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.